Mixed
SGLT-2 inhibitors reduce body weight and visceral adiposity in Asian patients with type 2 diabetes, making them a preferred therapeutic option for overweight or obese patients.
If you have Type 2 Diabetes and are overweight, ask your doctor about SGLT-2 inhibitors (like Jardiance, Farxiga, or Invokana). Unlike older diabetes meds that often cause weight gain, these drugs help you lose weight and reduce belly fat while managing your blood sugar.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity.
Why this rating
Supported by multiple randomized controlled trials, CV outcome trials, and pooled analyses.
Source
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Wayne Huey‐Herng Sheu et al. · Diabetes & Metabolism Journal · 2020
DOI 10.4093/dmj.2019.0208
More from this paper
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →